NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025
Nadeem R. Abu‐Rustum, Susana M. Campos, Sudha Amarnath, Rebecca C. Arend, Emma L. Barber, Kristin Bradley, Rebecca Brooks, Junzo Chino, Hye Sook Chon, Marta A. Crispens, Shari Damast, Christine M. Fisher, Peter J. Frederick, David K. Gaffney, Stéphanie Gaillard, Robert Giuntoli, Scott Glaser, Brooke E. Howitt, Lisa M. Landrum, Jayanthi Lea, Nita K. Lee, Gina Mantia-Smaldone, Andrea Mariani, David G. Mutch, Christa Nagel, Larissa Nekhlyudov, Karina Nieto, Chika Nwachukwu, Mirna Podoll, Kerry J. Rodabaugh, Ritu Salani, John O. Schorge, Scott M. Schuetze, Jean Siedel, Rachel Sisodia, Pamela T. Soliman, Stefanie Ueda, Renata R. Urban, Emily Wyse, Nicole R. McMillian, Vaishnavi Sambandam
Abstract
The NCCN Guidelines for Uterine Neoplasms provide recommendations for diagnostic workup, clinical staging, and treatment options for patients with endometrial cancer and uterine sarcoma. The NCCN Cervical Uterine Panel meets at least annually to review comments from reviewers within their institutions; examine relevant new data from publications, abstracts, and recent FDA approvals; and reevaluate and update recommendations. These NCCN Guidelines Insights summarize the panel's deliberations on the new FIGO 2023 staging system and updates on the new systemic therapy recommendations for the management of endometrial cancer.